Insider Trading Alert - LRCX, OMED And POOL Traded By Insiders - TheStreet

Yesterday, Oct. 27, 2015, 46 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $9.70 to $8,186,902.01.

Highlighted Stocks Traded by Insiders:

Lam Research (LRCX) - FREE Research Report

Anstice Martin B, who is President and CEO at Lam Research, sold 7,948 shares at $73.90 on Oct. 27, 2015. Following this transaction, the President and CEO owned 137,414 shares meaning that the stake was reduced by 5.47% with the 7,948-share transaction.

The shares most recently traded at $75.95, up $2.05, or 2.7% since the insider transaction. Historical insider transactions for Lam Research go as follows:

  • 4-Week # shares sold: 7,948
  • 12-Week # shares sold: 7,948
  • 24-Week # shares sold: 7,948

The average volume for Lam Research has been 2.8 million shares per day over the past 30 days. Lam Research has a market cap of $11.9 billion and is part of the technology sector and electronics industry. Shares are down 5.34% year-to-date as of the close of trading on Tuesday.

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing systems used in the fabrication of integrated circuits. The stock currently has a dividend yield of 1.6%. The company has a P/E ratio of 19.1. Currently, there are 11 analysts who rate Lam Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LRCX - FREE

TheStreet Quant Ratings

rates Lam Research as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, compelling growth in net income and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Lam Research Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

OncoMed Pharmaceuticals (OMED) - FREE Research Report

Gurney Austin, who is Officer at OncoMed Pharmaceuticals, sold 14,000 shares at $20.00 on Oct. 27, 2015. Following this transaction, the Officer owned 35,419 shares meaning that the stake was reduced by 28.33% with the 14,000-share transaction.

The shares most recently traded at $22.16, up $2.16, or 9.75% since the insider transaction. Historical insider transactions for OncoMed Pharmaceuticals go as follows:

  • 4-Week # shares bought: 11,210
  • 4-Week # shares sold: 14,000
  • 12-Week # shares bought: 24,350
  • 12-Week # shares sold: 14,000
  • 24-Week # shares bought: 24,350
  • 24-Week # shares sold: 18,000

The average volume for OncoMed Pharmaceuticals has been 171,200 shares per day over the past 30 days. OncoMed Pharmaceuticals has a market cap of $609.1 million and is part of the health care sector and drugs industry. Shares are down 0.87% year-to-date as of the close of trading on Tuesday.

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Currently, there are 2 analysts who rate OncoMed Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMED - FREE

TheStreet Quant Ratings

rates OncoMed Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

OncoMed Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pool (POOL) - FREE Research Report

Sledd Robert C, who is Director at Pool, sold 15,000 shares at $80.98 on Oct. 27, 2015. Following this transaction, the Director owned 26,954 shares meaning that the stake was reduced by 35.75% with the 15,000-share transaction.

The shares most recently traded at $81.79, up $0.81, or 0.99% since the insider transaction. Historical insider transactions for Pool go as follows:

  • 4-Week # shares sold: 2,054
  • 12-Week # shares sold: 2,054
  • 24-Week # shares sold: 8,054

The average volume for Pool has been 255,700 shares per day over the past 30 days. Pool has a market cap of $3.5 billion and is part of the consumer goods sector and consumer durables industry. Shares are up 27.87% year-to-date as of the close of trading on Tuesday.

Pool Corporation distributes swimming pool supplies, equipment, and related leisure products in North America, Europe, South America, and Australia. The company offers approximately 160,000 national brand and its own-branded products. The stock currently has a dividend yield of 1.27%. The company has a P/E ratio of 29.2. Currently, there are 2 analysts who rate Pool a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on POOL - FREE

TheStreet Quant Ratings

rates Pool as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, impressive record of earnings per share growth, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Pool Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.